HopeStage
Back to all studies
CompletedNCT05004896

Repeated ketamine infusions for treatment-resistant depression in people with bipolarity

About this title

Ketamine for Treatment-Resistant Bipolar Disorder

Read the official source — NCT05004896
Medication studyAges 21–65Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 21 years to 65 years.

Listed locations
Toronto and 2 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 4, 2022
Recruitment status
Completed
Enrollment listed in the registry
71
Sponsor
Joshua Rosenblat
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
From 21 Years to 65 Years
Official registry ID
NCT05004896
Official title
Show the full official title

Repeated Ketamine Infusions for Treatment-Resistant Bipolar Disorder: A Randomized, Double-blind, Midazolam-controlled, Phase II Clinical Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto · Whitby

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Joshua Rosenblat.

Did this study involve medication?

Yes. The study involved medication, including Ketamine Hydrochloride and Midazolam Hydrochloride.

Who was this study for?

Listed age limits: 21 years to 65 years.

Want to explore more studies?

Explore studies